Interferon alpha-8 (IFNA8)

Interferon alpha-8 (IFNA8) is a member of the Type I interferon family produced primarily by immune cells such as macrophages, and it plays a central role in the innate immune response to viral infection[1][6][7]. As a cytokine, IFNA8 binds to the type I interferon receptor complex (IFNAR1/IFNAR2) on the surface of target cells, activating intracellular Jak-STAT pathways that upregulate transcription of numerous interferon-stimulated genes (ISGs), which mediate diverse antiviral, antiproliferative, pro-apoptotic, and immunomodulatory effects[2][4]. These functions make IFNA8 important for defense against viral pathogens, and its activity can fine-tune immune responses in a cell type– and context–dependent manner[2][7]. IFNA8 is investigated, alongside other Type I interferons, both for its role in natural immune defense and as a therapeutic agent in diseases such as chronic viral infections, malignancies, and inflammatory or autoimmune disorders[4][8]. Like other interferon-α subtypes, its therapeutic use is associated with notable side effects including flu-like syndrome, hematologic suppression, liver enzyme elevation, neuropsychiatric symptoms, and risk of autoimmunity[4][8]. Interacting drugs are primarily clinical interferon α products (recombinant IFN-α formulations); some anti-angiogenesis or immunomodulatory regimens may be used in combination with type I interferons[10]. Distinct regulation of ISG expression by IFNA8 can be observed across different cell types, allowing for diversity and fine control of cellular defense and inflammation[2].

Other names

Interferon alpha-8IFNA8IFN-alpha-8IFN-alphaBInterferon alpha-BInterferon alpha-B2Interferon alpha-B'Interferon alpha type 201LeIF Binterferon α 8

Binds to type I interferon alpha/beta receptor (IFNAR1/IFNAR2) on target cells Activates Jak-STAT signaling leading to transcription of ISGs Induces proteins for antiviral defense, growth inhibition, apoptosis, and immune modulation